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Radiation diagnostics of sarcoidosis in modern conditions is CT, supplemented 
by radionuclide studies (SPECT, PET), ultrasound, MRI. The paper describes the 
classic signs of pulmonary sarcoidosis (according to the Statement on Sarcoidosis, 
1999), which have changed their characteristics due to the widespread use of 
CT: variants of lymphadenopathy, dissemination, interstitial involvement. New 
unfavorable forms of thoracic sarcoidosis are discussed: fibrous sarcoidosis (with 
a description of the variants of sarcoid fibrosis and their differences from other 
progressive pulmonary fibrosis) and progressive sarcoidosis (possible causes and 
patterns). Radiation semiotics of extrapulmonary and comorbid manifestations is 
touched upon.
Keywords: pulmonary sarcoidosis, systemic sarcoidosis, comorbidity in sarcoidosis, 
radiation diagnostics, computed tomography
1. Introduction
Sarcoidosis is a polysystemic inflammatory disease of unknown etiology, related 
by its morphological characteristics to the group of lymphotropic granulomatosis 
with the formation of noncaseating granuloma, most often the disease reveals, itself 
as pulmonary sarcoisosis (PS) manifestations [1, 2]. The clinical and radiation symp-
toms of PS are well studied and defined by the American Thoracic Society (ATS), the 
World Association for Sarcoidosis and Other Granulomatous Diseases (WASOG), 
the European Respiratory Society (ERS) and the Russian Respiratory Society [2–4]. 
On the basis of the traditional X-ray picture of the process, Scaddıng J.G. [5], 
identified 5 stages of PS, which are used to this day, in a modified version of the 
assessment by computed tomography (CT). In recent decades, due to the widespread 
use of CT in patients with РS, there have been revealed changes in the lungs that are 
not characteristic of this disease and go beyond the stages of its generally accepted 
radiological classification. According to various authors, the frequency of atypical 
forms of РS varies from 2–25% or more of all detected cases [6, 7]. In recent decades, 
there has been an increase in the number of cases of atypical and progressive vari-
ants of the course of sarcoidosis, including the formation of fibrosing sarcoidosis of 
the lungs, damage to vital organs (kidneys, heart, central nervous system) requiring 
transplantation, and an increase in mortality from sarcoidosis [8, 9]. The ineffective-
ness of the treatment has led to the identification of a separate form - refractory 
sarcoidosis [10]. Most often, sarcoidosis is treated by pulmonologists (since the 
main manifestation of the disease is РS), a thoracic radiologist who is well aware of 
the radiation semiotics of disseminated lung processes works with them. However, 
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sarcoidosis is systematic, which requires a pulmonologist to know about possible 
variants of damage to other organs and systems, and from a radiologist about the 
radial signs of their damage, the ability to analyze multimodal studies and draw up 
an optimal radiation algorithm to identify all systemic changes [11]. The incidence 
of organ damage in sarcoidosis varies across studies, which makes these figures not 
very reliable (this is probably due to the use of hospital design in most studies, which 
includes patients with sarcoidosis observed in certain clinics; studies using popula-
tion design, based on national or regional registers are considered to be the best). It 
is clear that the likelihood of extrathoracic lesions is very high and underestimated, 
since they are mostly favorable, asymptomatic (like most of the РS). Isolated 
extrathoracic lesions in sarcoidosis are very difficult. They mimic various diseases, 
are poorly recognized without the support of a pulmonologist, are confirmed only 
morphologically, are often the reason for multiple revisions of morphological data 
(they will not be considered in this study). The multisystem nature of the lesion can 
lead to a significant decrease in the patient’s quality of life [3]. Extrathoracic lesions 
in sarcoidosis require additional examination under the supervision of a physician 
of the relevant specialty. Now, the criteria for cardiosarcoidosis and neurosacoid-
osis have been published; there are no clear recommendations on the volume and 
methods of radiation studies in other localizations. Thus, in general clinical practice 
in the absence of symptoms, a basic eye examination is proposed for screening 
ocular sarcoidosis, a basic serum creatinine test for screening renal sarcoidosis, a 
serum alkaline phosphatase test for screening liver sarcoidosis, an ECG for detecting 
possible heart damage [4]. In determining the typical radiation semiotics of damage 
to various organs in sarcoidosis, the structured Delphi methodology is used, when 
the agreement of more than 70% of experts allows a consensus to be reached. This 
is necessary because a radiologist should be a member of a multidisciplinary team 
dealing with a patient with sarcoidosis, know the clinical manifestations, possible 
variants of systemic damage and the optimal radiation algorithm for examining 
patients with different risks.
While proceeding clinically favorably, sarcoidosis does not really bother the 
patient, however, comorbid lesions (neoplasms, infectious processes, PE) change 
both the clinical picture of the disease and its radiation signs [12, 13]. The different 
types of dissemination seen on CT scan suggest a comorbidity is present. To sim-
plify the assessment of systemic damage in sarcoidosis, attempts have been made 
to create diagrams that simplify the diagnosis. So, in the work of Schupp J.C., et al. 
[14], five clinical clusters of sarcoidosis were proposed: (1) damage to the abdomi-
nal organs, (2) damage to the eyes, heart, skin and central nervous system, (3) 
damage to the skeletal muscle and skin tissue, (4) involvement of the pulmonary 
and intrathoracic lymph nodes, and (5) extrapulmonary involvement. In 2014, the 
World Association for Sarcoidosis and Other Granulomatous Diseases (WASOG), 
according to the Delphi study, proposed a probability scale [15]: certain: the likeli-
hood of sarcoidosis causing this manifestation is at least 90% (e.g.: uveitis, bilateral 
hilar lymphadenopathy, perilymphatic foci on chest CT); probable: the probability 
of sarcoidosis is 50–90% (for example: paralysis of the seventh cranial nerve, 
edema of the lacrimal gland, localization of the process in the upper lobes or diffuse 
peribronchovascular infiltrates); possible: the probability of sarcoidosis is less than 
50% (for example: arthralgias, localized infiltration on radiographs). However, in 
practice, the use of these criteria is not always convenient. Studies in systemic and 
comorbid sarcoidosis suggest radiation multimodality (MRI, PET, SPECT, 67 Ga 
scintigraphy), however, CT with its various techniques (HRCT, functional tests, CT 
angiography) remains the main and at the same time expert method for its diagno-
sis, which allows and qualitatively answer the questions of the pulmonologist. The 
article discusses the changes detected during routine CT examination of patients 
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with sarcoidosis, to which a radiologist should draw the attention of the pulmon-
ologist. These findings can change the tactics of patient management and require 
additional radiation studies.
2. Radiation patterns of modern sarcoidosis (alphabet)
We analyzed the data of radiological studies of 873 patients observed with a 
diagnosis of sarcoidosis from 2006 to 2021 at the St. acad. I.P. Pavlova. The observa-
tion period ranged from 6 months to 22 years. The average age of the patients was 
47.2 ± 10.2 years (f / m - 500/373). All patients underwent CT, a pulmonary func-
tion tests (PFTs), and echocardiography, in some patients, if necessary, additional 
radiation studies (MRI, PET, SPECT) were performed. CT data revealed a number 
of radiation signs of typical (determined by WASOG) and not contradicting (prob-
able and possible by WASOG) РS, which a radiologist needs to know to interpret 
radiation data correctly. The typical nature of the lesion suggests the possibility of 
making a diagnosis without biopsy (since even the most benign biopsy options are 
not desirable due to the development of scars at the site of the surgical injury and 
the likelihood of a decrease in FVC and DLСО). Radiation signs that do not contra-
dict the manifestations of sarcoidosis require the convening of a multidisciplinary 
council and a decision to conduct histological verification, atypical radiation mani-
festations need to be supplemented with morphology. An analysis of the results of 
radiation research revealed the following radiation features of modern РS:
The defeat of the intrathoracic lymph nodes: typical (58.6%) were symmetri-
cal lesions of the peritracheobronchial, paraaortic, intrapulmonary groups (with 
the obligatory involvement of bronchopulmonary lymph nodes), the absence of 
necrotic changes in the structure, the preservation of the integrity of the lymph 
node capsule, the preservation of the surrounding cellular spaces (Figure 1a), the 
absence of compression adjacent vessels and bronchi even with a large increase in 
lymph nodes (Figure 1c), uniform accumulation of contrast agent in them during 
all phases of intravenous bolus contrast enhancement (Figure 1a) and high metabo-
lism of 18FDG on PET (Figure 1b). Not contradicting the diagnosis of sarcoidosis is 
the presence of calcifications in the structure of the lymph nodes (25.2%) (Figure 
1d), the asymmetry of their lesions (5.0%) (Figure 1e), the lesion of non-character-
istic groups (retrosternal, paraesophageal) in combined with the defeat of typical 
groups (2.3%) (Figure 1f).
Figure 1. 
Radiation picture of the defeat of the lymph nodes with PS (explanations in the text).
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Lung lesion with РS consists of two components: the presence of foci and 
lesions of the interstitium. Perilymphatic foci were typical - small (up to 3 mm), 
of the same type, along the interlobular septa, along the bronchi, vessels, pleura 
(46.3%) (Figure 2a), large foci of irregular oval or trapezoidal perilymphatic 
arrangement (67.0%) (intrapulmonary lymph nodes), which regressed more slowly 
than other foci (Figue 2b), fusion of small foci into large ones with indistinct con-
tours (17.1%) (symptom of “galaxy”) (Figure 2c), fusion of foci into peribroncho-
vascular masses - sarcoids (11.9%) (Figure 2d). Not contradicting the diagnosis of 
sarcoidosis is the identification of flat subpleural foci (2.2%) (plaques) (Figure 2e),  
and the presence of calcifications in the foci (1.2%) (Figure 2f). The presence 
of cavities in the foci (0.2%) also did not contradict the diagnosis of sarcoidosis: 
Patient A., 23 g. 2008 (Figure 2g) - typical intrathoracic lymphadenopathy, 
Figure 2. 
Radiation picture of lung lesions with PS (explanations in the text).
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perilymphatic dissemination with the formation of a symptom of “galaxy”, cavities 
in the foci, 2011 (Figure 2h) - regression after steroid therapy with preservation 
of post-sarcoid perilymphatic fibrous foci, 2013 (Figure 2i) progression of the 
process: an increase in perilymphatic dissemination, edema of the peripheral 
pulmonary interstitium, the formation of sarcoids. The lesion of the interstitium 
in sarcoidosis can be both of temporary (edema, cell infiltration) and of permanent 
character (fibrosis) character. Sarcoidosis is characterized by a lesion of the central 
interstitium with the presence of peribronchovascular “couplings” and sarcoids, 
damage of the peripheral interstitium (thickening of the interlobular - the wall of 
the secondary pulmonary lobe and intralobular - acinar septa) is not typical and is 
an unfavorable symptom that predicts a high likelihood of developing respiratory 
insufficiency at advanced stages. Manifestations of sarcoid alveolitis (10.2%) - 
compaction of the peripheral pulmonary interstitium of the “ground glass” type, 
due to the presence of edema and cellular infiltration before the formation of 
granulomas (Figure 2j), or the presence of small perilymphatic foci in the wall of 
the alveoli (Figure 2k) with the possibility of forming fibrosis of the peripheral 
interstitium (Figure 2l). Persistence and increase in edema of the peripheral pul-
monary interstitium in sarcoidosis is an unfavorable scenario for the development 
of the disease, leading to the formation of interstitial fibrosis: Patient K., 49 years 
old. 2016 (Figure 2m), 2018 (Figure 2n), 2020 (Figure 2o), the progression of 
the process: regression of lymphadenopathy, an increase in perilymphatic dis-
semination, edema of the peripheral pulmonary interstitium with the formation of 
fibrosis, in 2020. - the appearance of shortness of breath, dry cough, a decrease in 
DLСО to 68% of D. Not contradicting the diagnosis of sarcoidosis is the asymmetry 
of the lesions of the lung tissue and interstitium (7.2%) (Figure 2a).
The transition of РS in stages III and IV is accompanied by fibrosis processes 
(which, in a number of patients, requires the inclusion of the disease in the category 
of progressive pulmonary fibrosis). Typical are fibrotic changes in the central 
pulmonary interstitium (at the sites of granuloma localization) with the formation 
of peribronchovascular fibrous couplings (4.7%) (they differ little from sarcoids, 
which can regress; within 6 months) with the formation in these areas of traction 
bronchiectasis of large bronchi (since these are the basal regions), a decrease in the 
volume of the upper and middle pulmonary fields, in contrast to IPF, in which the 
lower lobes are more affected. The type of pulmonary volume reformatting is better 
seen when constructing image reformation (MPR, MinP). Calandriello L., Walsh 
S.L.F. [16] suggest that posterior displacement of the main or upper lobe bronchus 
with a decrease in the volume of the posterior segments of the upper lobes is a typical 
feature of fibrous sarcoidosis. The volume of fibrosis of the lung tissue in stage IV 
РS is very different: minimal “gentle” fibrous changes of a linear nature (Figure 3a), 
peribronchovascular fibrous couplings (Figure 3b), massive peribronchovascular 
fibrous changes, forcing to change the course of the vessels in the anterior regions to 
rounded (“vortex” symptom) (Figure 3c).
Figure 3. 
Radiation picture typical fibrotic changes in РS (explanations in the text).
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Not contradicting the diagnosis of sarcoidosis is the identification of a “hon-
eycombing lung”, which is rarely observed (1.9%), has a short length and can be 
localized both in the subpleural and in the basal regions. Preservation of lymph-
adenopathy and perilymphatic foci is possible at III and IV stages of the disease 
These forms belong to the unfavorable variants of the clinical course - fibrosing 
and progressive sarcoidosis. According to Xu L. et al. [17], in contrast to the “hon-
eycombing” in the case of usual interstitial pneumonia (UIP), the “honeycomb” in 
РS is located centrally and is accompanied by traction expansion of large bronchi 
(bronchiectasis). It was noted that fibrous and active granulomatous patterns are 
present in the final stage of РS. Abehsera M. et al. [18] believe that two main models 
of fibrosing sarcoidosis of the lungs have characteristic radial and functional fea-
tures: in peribronchovascular fibrosis, obstructive disorders in PFTs with a decrease 
in FEV1, an increase in OOL, with the formation of a “honeycombing lung” - 
restrictive disorders with PFTs with a decrease in FVC, DLCO. They also noted that 
progressive pulmonary sarcoidosis was characterized by the presence of chronic 
Aspergillus or bacterial infection. D. Valeyrea et al. [19] highlighted the same two 
main CT patterns of progressive pulmonary sarcoidosis with different functional 
profiles, noting that they may be with or without signs of activity, concluding that 
an algorithm based on pulmonary function and CT, allows predicting survival in 
progressive sarcoidosis. According to our data, 8.9% of patients had a severe course 
of the disease with dyspnea and radiation signs of fibrosis, which were not typical 
for the classical version of the course, the traditional radiation pattern and the exist-
ing X-ray classification of PS. Our analysis allowed us to identify several models of 
atypical pulmonary sarcoidosis.
Model of interstitial edema (IE): edema and cellular infiltration of the 
peripheral pulmonary interstitium (1.5%) was manifested by the presence of small 
perilymphatic dissemination, merging into a picture similar to the manifestations 
of interstitial pulmonary edema (clinically also similar to it - shortness of breath, 
dry cough). Perhaps the fibrous form of sarcoidosis is the outcome of the intersti-
tial-edematous form in patients who did not receive adequate timely therapy, or 
the result of a comorbid course of sarcoidosis (with viral pneumonia, concomitant 
occupational pathology) (Figure 4a).
Model of idiopathic pulmonary fibrosis (IPF) - fibrosis of the peripheral 
pulmonary interstitium (1.0%): persistent CT-picture of “ground glass” opacity 
Figure 4. 
Radiation picture of possible fibrotic changes in PS (explanations in the text).
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(intralobular fibrosis), traction bronchiolyectasis, “honeycombing lung” in 
combination with lymphadenopathy of the peritracheobronchial groups. With 
the IPF model of sarcoidosis, there were noticed less severe than with IPF clinical 
symptoms (moderate dyspnea), a positive reaction to steroid therapy (probably as 
a result of regression of sarcoid granulomas that exist even at advanced stages of 
the process), moderate restrictive disorders in PFTs: decrease in DLCO to 55% of 
D, CT-signs of pulmonary hypertension (SDPA 30.3 + 3.8 mm Hg). Morphological 
examination revealed manifestations of fibrosing lung disease (fibrosis of the 
alveolar septa, formation of a “honeycomb lung”) and sarcoid granulomas 
(Figure 4b).
Model of hypersensitive pneumonitis (HP) - fibrosis of the central intersti-
tium (1.3%). In the areas of peribronchovascular fibrosis typical for PS, the pres-
ence of a “honeycomb lung” with “honeycombs” of a large size was noted. These 
patients were also characterized by a long-term slow decrease in DLCO (up to 65% 
of D) and the associated gradual deterioration of health with an increase in short-
ness of breath and dry cough (Figure 4c).
PP + IPF model - fibrosis of the central and peripheral interstitium (0.9%). 
Fibrosis and “honeycomb” in the upper-posterior basal regions were combined with 
the presence of “honeycomb lung” in the subpleural areas. Changes of this type 
were accompanied by pronounced clinical changes (shortness of breath, decreased 
exercise tolerance, dry cough), the formation of severe pulmonary hypertension 
(with an increase in systolic pressure in the pulmonary artery to 62 ± 17 mm Hg), a 
decrease in DLCO (up to 50% of D) (Figure 4d).
The model of pneumoconiosis is a fibrocavitary form of PS (1.1%). The 
formation of cavities in the “sarcoids” (as a result of trophic disorders, or second-
ary sarcoid vasculitis). The shape of the cavities is irregular, the wall is varied. In 
some patients, there was a rapid regression of the process when steroid therapy was 
prescribed. In some patients, the changes progressed. Clinically, it proceeded calmly 
in most of the patients, in a number of patients it was accompanied by hemoptysis 
(Figure 4e).
A model of progressive PS (3.0%) - a combination of all stages at the same 
time - lymphadenopathy of the peritracheobronchial groups typical for sarcoidosis, 
perilymphatic dissemination in the lung tissue, massive fibrous changes of a severe 
nature in the upper-posterior basal regions on both sides with the formation of trac-
tion bronchiectasis. Clinically, these patients had a chronic recurrent unfavorable 
course of the disease, with wave-like radial changes in the increase and regression 
of perilymphatic dissemination and lymphadenopathy, were steroid -dependent - 
more often they were not treated at all (Figure 4f).
According to M.H. Jeon, et al. [12], interstitial lung disease with pulmonary fibrosis 
and pulmonary hypertension was associated with increased mortality, with pulmonary 
fibrosis accounting for 9.0% of deaths in sarcoidosis. According to Sève P., et al. [20] 
fibrotic changes on CT in sarcoidosis correlate with PFTs, 6-minute walk test data 
(6MWT) and the results of the St. George respiratory questionnaire. Thus, a decrease in 
the ratio of the forced expiratory volume in one second (FEV1)/FVC may be associated 
with significant deformation of the bronchi, their stenosis due to fibrosis, due to diffuse 
bronchial granulomatosis, compression of the bronchi with a significant increase in 
the lymph nodes of the mediastinum, and as a result granulomatous bronchiolitis or 
bronchial hyperreactivity. Low DLCO values  may result from diffuse parenchymal 
lesions or sarcoid alveolitis.
Calandriello L., et al. [21] write about new trends in the assessment of SP, 
pointing to new directions: attempts to assess the state of the lung tissue in 
sarcoidosis using artificial intelligence (radiomics), the wider use of low-dose CT 
and MRI programs of the chest.
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The algorithm of radiation examination for sarcoidosis suggests performing CT 
to assess intrathoracic changes with the analysis of signs of damage to the organs of 
the upper abdomen included in the scan area (liver, spleen, lymph nodes, kidneys), 
supplemented by ultrasound of the abdomen, if necessary, CT examination of the 
chest and abdomen in the conditions of intravenous bolus contrast enhancement 
and the use of MRI, PET, SPECT with gallium as reserve methods for assessing the 
systematicity of the lesion and comorbidity. The decision to appoint additional 
radiation studies is made by a multidisciplinary council. According to Kobak S. 
[22], the prevalence of extrapulmonary sarcoidosis is up to 80%. However, it is not 
known how to assess the systemic nature of the lesion, because almost all patients 
have minimal extrathoracic radiation and clinical manifestations. It is believed that 
the skin, eyes, heart and musculoskeletal system are the most commonly affected 
organs after the lungs. There were reported rare lesions of the gastrointestinal tract 
and isolated cases of sarcoidosis of the prostate, bladder, bone marrow and thyroid 
gland. Multiple organ damage is always chronic and more severe, and can lead to a 
serious disability or potentially fatal consequences. At the same time, according to 
Jeon M.H., et al. [12], there is no data on a significant difference in PFTs indicators 
in patients with and without systemic manifestations. According to C.-W. Li, et al. 
[23], patients with PS and extrapulmonary lesions had more pronounced changes in 
CT examination in patients with stage II of PS. It is not known which of the combi-
nations of PS and systemic manifestations are the most dangerous. According to our 
data, systemic lesion in PS is accompanied by changing the favorable course of the 
disease to a more severe one, symptoms of damage to other organs come to the fore, 
but the pulmonological multidisciplinary council continues to play a decisive role in 
the diagnosis. Thoracic changes are the most specific and make it possible to make 
a diagnosis, while extrathoracic changes may be similar to other processes. Most of 
the extrathoracic changes are clinically as favorable as classical PS and are detected 
by chance during additional studies (ultrasound, CT, MRI of the abdomen and pel-
vis). Others have a vivid clinical picture (neurosarcoidosis, sarcoid cirrhosis of the 
liver, sarcoid sialoadenitis, sarcoid uveitis), and some may manifest as sudden death 
(cardiac sarcoidosis). In all cases, the X-ray archive is very important, since at the 
time of extrathoracic symptoms, PS as a rule has already been delitescent for some 
time and can be identified retrospectively, even if it was overlooked in the initial 
analysis. Numerous attempts have been made to combine the symptoms of damage 
to different organs in sarcoidosis [9, 11, 14, 22, 23]. According to our data, the most 
frequent X-ray findings during chest CT were extrathoracic lymphadenopathy and 
damage to the parenchymal organs of the abdomen.
Extrathoracic lymphadenopathy (7.3%): neck, axillary groups, abdomen, 
pelvis has always been combined, with intrathoracic changes, according to our data. 
The characteristics of lymph node lesions were the same as those of intrathoracic 
ones (multiplicity of affected nodes in the group, no violation of the structure and 
integrity of the capsule, uniform accumulation of contrast agent in all phases of 
contrast enhancement, including delayed, high metabolism of 18-FDG on PET). 
Patient N., 29 years old. Lymphadenopathy of the peritracheobronchial groups, 
perilymphatic dissemination in the lung tissue are typical manifestations of stage 
II PS (Figure 5a), lesions of the lymph nodes of the extrathoracic groups; axillary 
(Figure 5a), deep and superficial cervical groups on both sides (Figure 5b), celiac 
and retroperitoneal groups (Figure 5c).
The lesion of the parenchymal organs of the abdomen in sarcoidosis is a frequent 
accidental finding during CT of the chest organs, because the liver, spleen and 
kidneys are partially covered by the scanned area. Spleen lesion in sarcoidosis may 
appear as splenomegaly and localized changes. A study by Tetikkurt C., et al. [24] 
showed that diffuse spleen lesion was associated with PS and other extrapulmonary 
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Figure 5. 
Radiation picture of systemic manifestations in sarcoidosis (explanations in the text).
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manifestations and appears to be a risk factor for chronic sarcoidosis. Changes in the 
blood count in sarcoidosis (leukopenia, lymphopenia, anemia, thrombocytopenia, 
and / or pancytopenia) increase the likelihood of bone marrow damage (rare) and 
the development of splenomegaly. According to our data, damage to the spleen was 
detected frequently (52.3%). The degree of enlargement of the spleen was different 
(up to hypersplenism - 2.0%), which could be an indication for splenectomy due to 
the risk of rupture and the appearance of clinical symptoms - dull ache in the left 
hypochondrium, shortness of breath, chronic fatigue. Even when the normal size 
of the spleen was maintained in one third of patients with sarcoidosis, PET showed 
an increase in the metabolism of 18-FDG, which was a sign of its granulomatous 
lesion. Rarely foci of low soft tissue density were detected in the spleen, accumulat-
ing contrast agent to a lesser extent than unchanged parenchyma (1.6%), regressing 
independently or during therapy, spleen infarctions (0.3%). The spleen lesion in 
sarcoidosis - hypersplenism (Figure 5d), foci in the spleen (Figure 5e), increased 
18-FDG in the not enlarged spleen on PET (Figure 5f).
The liver is often affected in sarcoidosis. A meta-analysis by E.D. Crouser, et 
al. [4] showed that liver function tests in sarcoidosis patients were abnormal in 
12% of patients, and among those who received a liver biopsy, granulomas were 
found in 96%. According to Tadros M., et al. [25], in biopsy and autopsy studies of 
patients with systemic sarcoidosis, liver involvement was found in about 50–80%, 
some patients may develop end-stage liver disease, and liver transplantation is 
required. it accounts for about 0.012% of the total number of liver transplants in the 
United States. P. Sève, et al. [20] note that portal hypertension occurs in 3 to 20% 
of cases of sarcoid hepatitis and may result from obstruction of the portal venous 
system due to significant enlargement of the lymph nodes of the hepatic hilum; 
the development of secondary ischemia, causing cirrhosis and focal fibrosis, or 
arteriovenous shunts, which increase portal blood flow. In our study, liver damage 
in sarcoidosis, as well as damage to the spleen, was most often asymptomatic and 
manifested by hepatomegaly (24.3%), which was accompanied by an increase in the 
metabolism of 18-FDG, foci of reduced soft tissue density that did not accumulate 
contrast agent (1.2%). A rare and tragic situation was the development of sarcoid 
hepatitis and subsequent cirrhosis, identified in 4 patients (0.4%) and manifested 
by diffuse changes in the liver parenchyma due to small and large-nodular rear-
rangements, hepatosplenomegaly, portal hypertension, ascites. To assess the 
progression of these changes, ultrasound elastography and MRI with intravenous 
contrast enhancement were also used. Patient Sh., 45 years old. Sarcoid cirrhosis of 
the liver, hepatosplenomegaly, portal hypertension. Lymphadenopathy (significant, 
symmetrical increase in peritracheobronchial groups, uniform accumulation of 
contrast agent in them, no signs of compression of adjacent vessels and bronchi), no 
changes in the lung tissue are typical manifestations of PS I st. (Figure 5g and h), 
an increase in the size of the liver and spleen, restructuring of the liver due to the 
presence of multiple nodes that unevenly accumulate contrast agent, hypertrophy 
of the caudate lobe are manifestations of sarcoid cirrhosis of the liver; expansion of 
the portal, splenic veins are manifestations of portal hypertension (Figure 5i).
E.D. Crouser, et al. [4] showed that renal impairment was detected in 7% 
of patients with sarcoidosis. Two mechanisms of renal dysfunction in patients 
with sarcoidosis are considered: parenchymal granulomatous inflammation and 
changes in calcium metabolism leading to nephrocalcinosis and nephrolithiasis. A 
meta-analysis by K. Al-Kofahi and P. Korsten [11] showed that 3.6% of sarcoidosis 
patients had nephrolithiasis at the first visit. They also described rare manifesta-
tions of kidney damage in sarcoidosis: pseudotumors or mechanical compression 
of the urinary tract by significantly enlarged lymph nodes with the formation of 
hydronephrosis. In our study, such forms of lesion were not identified, the revealed 
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changes were nonspecific: nephrolithiasis (2.8%), secondary renal wrinkling (as 
a result of a long course of tubolointerstitial sarcoid nephritis) (1.3%). Patient A., 
61 years old, histologically verified sarcoidosis, fibrous form of PS IV st., neurosar-
coidosis, chronic sarcoid tubulointerstitial nephritis: fibrous manifestations in the 
lungs that do not contradict PS: “honeycomb” formation in the hilar regions on both 
sides, minimal hilar lymphadenopathy (Figure 5j and k), wrinkling of the paren-
chyma of the left kidney partially included in the scan area (Figure 5l).
Polysystemicity presupposes the lesion of other organs, so, according to Lee J.K.T., 
et al. [26], an autopsy found sarcoidosis of the pancreas, intestines and testicles in 
5% of patients. In our study, pancreatic sarcoidosis was suspected in 1 patient with 
increased metabolism of 18-FDG on PET, intestinal sarcoidosis was not detected, 
testicular sarcoidosis was an accidental finding during PET in 2 patients (0.2%) 
(increased metabolism 18 -FDG) and not manifesting clinically. Patient I., 46 years 
old. Systemic sarcoidosis. Lymphadenopathy of the peritracheobronchial groups, 
perilymphatic dissemination in the lung tissue are typical manifestations of SP II st. 
(Figure 5m), the absence of anatomical changes in the testes on CT (Figure 5n), high 
metabolism of 18-FDG in them on PET (Figure 5o).
Neurosarcoidosis occurs in 3–9% of patients with systemic sarcoidosis (in our 
study, in 1.1%). Its clinical manifestations are diverse, since any part of the nervous 
system (brain, meninges, cranial nerves, spinal cord, peripheral nerves) can be 
affected. CNS lesion predominates over PNS lesion; these lesions usually do not 
overlap. According to M. Ramos-Casals, et al. [27], systemic manifestations are 
characterized by a combination of damage to the eyes and the central nervous sys-
tem, or a combination of damage to the liver and spleen and damage to the periph-
eral nervous system. According to Acharya N.R., et al. [28], ocular sarcoidosis was 
detected in 26% of patients with sarcoidosis, with anterior uveitis being the most 
common pathology (53%). Undoubtedly, the criteria proposed by Stern et al. [29], 
for a certain, probable and possible neurosarcoidosis will simplify the formulation 
of this complex diagnosis. Dierkes-Globisch A., et al. [30] showed a statistically 
significant trend towards a higher incidence of women in patients with CNS lesions 
and a higher incidence of kidney damage in patients with PNS lesions. Diverse 
radiation patterns in neurosarcoidosis require a multimodal and multidisciplinary 
approach. Patient M., 27 years old, complaints about general weakness, unsteadi-
ness when walking, drowsiness, lethargy, rare dry cough, hearing loss in the left ear, 
thirst up to 5–9 liters per day, polyuria up to 9 liters per day. Lymphadenopathy of 
the peritracheobronchial groups, perilymphatic dissemination in the lung tissue are 
typical manifestations of SP II st. (Figure 5p). On CT, MRI (Figure 5q–u) - peri-
ventricular sarcoids (maximally around the anterior horns of the lateral ventricles, 
more on the left), pituitary sarcoidosis (with manifestations of diabetes insipidus 
and diabetes), trigeminal nerve on the right.
Cardiac sarcoidosis is an underestimated manifestation of sarcoidosis 
that can manifest as sudden cardiac death. According to Mehta D. et al. [31], 
screening for cardiac sarcoidosis includes cardiac MRI (CMR) and PET with 
18 F-fluorodeoxyglucose (FDG-PET), ECG, echocardiography. It is noted that 
patients with delayed accumulation of gadolinium on MRI are at risk of adverse 
events, even with preserved left ventricular ejection fraction. According to Juneau 
D. [32], atrial involvement was seen in 9–50% cases of sarcoid. Birnie D.H. [33], 
notes that coronary arteries are usually normal, but extensive myocardial damage in 
sarcoidosis can lead to dilated cardiomyopathy. Radionuclide imaging with gallium 
67, thallium 201, technetium are alternative tests for diagnosing and monitoring 
cardiac sarcoidosis that are useful when MRI is contraindicated or unavailable [11]. 
Patient B., 47 years old, the disease debuted with recurrent pulmonary embolism, 
repeated infarctions of the anterior wall of the left ventricle with the formation 
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of a left ventricular aneurysm and the development of heart failure refractory to 
therapy. Six months later, during surgery - linear plasty of the left ventricular aneu-
rysm and removal of the left ventricular thrombus, a biopsy of the left ventricular 
myocardium was performed, and histological examination revealed epithelioid 
cell granulomas. After 10 months from the onset of the disease, CT examination of 
the chest organs revealed borderline mediastinal lymphadenopathy and changes in 
the lung tissue characteristic of SP II st. (Figure 5v–x). Also, there is an expansion 
of the cavities of the heart, trunk (34 mm) and large branches of the pulmonary 
artery, manifestations of interstitial stagnation, left-sided pleural effusion - mani-
festations of cardiomegaly, pulmonary hypertension, heart failure.
The relationship between the radiation signs of SP and comorbid processes 
changes the radiation pattern of both diseases. The most common comorbid 
processes in sarcoidosis are COPD, neoplasms, infectious processes, IPF and PE. 
All these comorbid conditions can have manifestations of disseminated chest 
lesions, complicating the differentiation of these diseases [12, 13]. The most com-
mon comorbid pathology in SP is acute PE, recurrent PE (RTE) and pulmonary 
hypertension, which can be caused by both sarcoidosis itself and chronic embolism 
(CTEPH). According to E.D. Crouser, et al. [4], echocardiography reveals signs of 
PH (high systolic pressure in the pulmonary artery) in 29% of patients with sar-
coidosis. In his systematic review, Baughman R.P., et al. [34], noted a relationship 
between PH and the severity of lung disease (a decrease in FVC and DLCO cor-
related with the degree of PH). This is supported by S. Kobak [22], who noted that 
in patients with sarcoidosis, DLCO <60% may be a predictor of pulmonary hyper-
tension. At the same time, according to P. Sève, et al. [20], increased pulmonary 
pressure may be associated with the sarcoid lesion itself: granulomatous lesions of 
the pulmonary vessels, a consequence of infiltration of the pulmonary parenchyma 
or compression by enlarged lymph nodes of large branches of the pulmonary artery 
in the mediastinum.
Acute PE, detected in our study in 3.3% of patients, caused the development of 
lobular pulmonary infarctions. Such changes can simulate a disseminated process 
(including sarcoidosis), conceal and be concealed behind sarcoid perilymphatic  
dissemination: patient K., 57 years old, SP III st., complicated by PE, a marker 
associated with a decrease in fibrinolytic activity. Multiple contrasting defects of the 
branches of the pulmonary artery on both sides - thrombotic masses causing their 
dilation, dilatation of the trunk of the pulmonary artery and its large branches -  
manifestations of PH (Figure 6a), perilymphatic dissemination characteristic of 
sarcoidosis and lobular infarctions of the lung characteristic of acute PE (Figure 6b), 
the source is a thrombus in the inferior vena cava (Figure 6c).
Pulmonary hypertension, often accompanied by IV st., fibrosing and progres-
sive sarcoidosis and was detected in 7.3% of patients: patient D., 59 years old. Grade 
IV SP, CTEPH. Typical manifestations of SP IV st. are peribronchovascular fibrotic 
changes with the formation of traction bronchiectasis, volume remodeling with a 
decrease in the upper lobes and the formation of vascular torsion in the anterior 
regions - a “vortex” symptom (Figure 6d). Parietal contrast defect (long-term 
thrombotic masses) in a significantly dilated pulmonary artery trunk (Figure 6e). 
High degree of pulmonary hypertension: on a single CT scan, the aortic arch and 
the extended pulmonary artery trunk (Figure 6f).
The combination of sarcoidosis with neoplasms is rare (in our study - in 9 
patients (1.0%). Combinations of sarcoidosis with various lymphoproliferative 
processes (lymphomas, leukemia), neoplasms of various localizations (which 
apparently are not related to each other), cancers are described. For example, 
Jamilloux et al. [35] note that lymphoma is a rare cause of death in sarcoidosis. 
Against the background of perilymphatic dissemination, it is difficult to identify 
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Figure 6. 
Radiation picture of comorbid manifestations in SP (explanations in the text).
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metastatic lesions, the basis of diagnosis is the hematogenous nature of the spread 
of metastases (we did not encounter the combination of sarcoidosis with lym-
phogenous metastatic lesions, perhaps it was not recognized due to the uniformity 
of the radiation pattern.) In 3 patients (0.3%) with a primary detected neoplasm, 
signs of sarcoid dissemination were determined, which could be due to the primary 
detection of sarcoidosis (finding) or a sarcoid reaction with some of the anti-cancer 
drugs. The use of PET did not help in this situation, because it increased metabo-
lism of 18-FDG in sarcoidosis and oncological processes was equally high: patient 
I., 45 years old, chest CT - a typical picture of SP II st. - lymphadenopathy of the 
peritracheobronchial groups, peribronchovascular sarcoids (has had sarcoidosis 
since 2015, without significant X-ray dynamics) (Figure 6g). CT scan of the neck 
- conglomerate of lymph nodes of the middle deep cervical group on the right: 
large size, asymmetry, accumulation of contrast agent along the capsule with the 
presence of irregularly shaped necrotic masses in the center that do not accumulate 
contrast agent (Figure 6h), high metabolism of 18-FDG - poorly differentiated 
squamous cell cancer of the lateral wall of the oropharynx with secondary lymph-
adenopathy (Figure 6i).
The combination of sarcoidosis with IPF (and other progressive pulmonary 
fibrosis) is a rare, poorly understood situation. It is not clear whether the processes 
of fibrosis in the lung tissue are triggered by sarcoidosis itself, or whether these 
are two different diseases. As a rule, carrying out morphological verification also 
does not clarify the picture, since it identifies both sarcoid granuloma and signs of 
pulmonary fibrosis. Differential diagnosis with a fibrosing granulomatous process 
(hypersensitive pneumonitis) is also difficult, because it is often not possible to 
determine the cause of exogenous exposure. In our study, such a combination was 
found in 1.9% of patients. Patient V., 34 years old, histologically verified sarcoid-
osis. On CT from 2017 - perilymphatic dissemination (small foci, sarcoid on the 
left, manifestations of sarcoid alveolitis in the lower lobe on the right), lymphade-
nopathy of peritracheobronchial groups (Figure 6j–l). On CT from 2019. - multidi-
rectional dynamics - regression of perilymphatic dissemination (traces in the form 
of small perilymphatic foci of a fibrous nature remain), an increase in interstitial 
changes in the lower-posterior subpleural regions on both sides - manifestations of 
progressive pulmonary fibrosis (Figure 6m–o).
For sarcoidosis, combinations with pulmonary inflammatory processes, both 
nonspecific and specific, are rare. The most common were the combination of 
sarcoidosis with COVID-19 lung damage (5.1%) and the formation of mycetomas in 
the sarcoid cavities (1.6%). The presence of mycotic lesions worsens the course of 
sarcoidosis due to toxic-allergic effects and the possibility of developing pulmonary 
hemorrhage. So, Jamilloux et al. [35], note that hemoptysis due to mycetoma can 
cause death in sarcoidosis. E. Criado, et al. [6], classifies sarcoidosis with manifesta-
tions of aspergillosis as an atypical radiation sign of sarcoidosis. The formation of 
mycetes in the fibrous sarcoid cavities with the appearance of symptoms of “sickle 
enlightenment” and “rattle” should force a pulmonologist to add antimycotic 
therapy: variants of mycetes in the sarcoid cavities (Figure 6p–r).
There is no increased risk of viral infection in sarcoidosis, however, during the 
COVID-19 pandemic, some patients with sarcoidosis have suffered this comorbid 
pathology. An analysis by Robert P. Baughman, et al. of five surveys of US and 
European survivors of sarcoidosis with COVID-19 [13] provided evidence that the 
incidence of COVID-19 infection in patients with sarcoidosis was higher than in 
the general population. They also noted that of the spectrum of immunosuppres-
sive therapies taken by sarcoidosis patients, only rituximab was associated with an 
increased risk of COVID-19 infection. There was no association between predni-
sone intake and the development of COVID-19, regardless of the prescribed dose 
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(≥ 10 and < 10 mg / day). We have identified three main options for the combina-
tion of COVID-19-sarcoidosis: exacerbation of the course of sarcoidosis against 
the background of COVID-19 lesions; a combination of radiation signs typical of 
COVID-19 and sarcoidosis; accidental detection of PS against the background of 
COVID-19. In patients with sarcoidosis who are prone to developing pulmonary 
fibrosis, as well as in patients with IPF, COVID-19 could aggravate the course of the 
process and trigger the course of fibrotic changes.
Patient L., 43, histologically verified sarcoidosis. CT from 2014 (Figure 6s) -  
typical manifestations of PS with the presence of hilar lymphadenopathy and sar-
coid alveolitis. CT scan from 2018 (Figure 6s) shows regression of the disease. On 
CT from 06.06.2020 (PCR on RNA SARS-CoV-2 (+) (Figure 6u) - bilateral edema 
of the peripheral and central pulmonary interstitium - CT picture of “ground glass” 
opacity - manifestations of sarcoid alveolitis overlapping small focal perilymphatic 
dissemination, lymphadenopathy of peritracheobronchial groups (significant, 
symmetrical, without violating the integrity of the capsule and the structure of the 
nodes) - exacerbation of sarcoidosis against the background of COVID-19.
Patient V., 68 years old, histologically verified sarcoidosis. CT scan from 2020 
(Figure 6v) - typical manifestations of SP III st. with the presence of peribroncho-
vascular fibrotic changes with the formation of traction bronchiectasis, moderate 
hilar lymphadenopathy, perilymphatic dissemination. Areas of interstitial infiltra-
tion in the subpleural regions on both sides - manifestations of COVID-19 lesions 
(PCR on RNA SARS-CoV-2 (+) (Figure 6w). On CT from 2019 (Figure 6x) changes 
characteristic of COVID- 19 were not identified.
Patient A., 62 years old, histologically verified sarcoidosis. CT scan from 2019 
(Figure 6y) - manifestations of SP II st. with the presence of perilymphatic small 
focal dissemination, hilar lymphadenopathy, PH. CT from 2020 (Figure 6z) - areas 
of interstitial and alveolar infiltration in the subpleural and nuclear regions on 
both sides - manifestations of COVID-19 lesion (PCR on SARS-CoV-2 (+) RNA. On 
CT from 2021 (Figure 6!) - regression of COVID-19 lesions, partial regression of 
perilymphatic dissemination and hilar lymphadenopathy, but an increase in signs of 
PH, fibrosis of the central and peripheral interstitium.
3. Conclusions
The sarcoid alphabet is an attempt to fully represent the radiation patterns of 
modern sarcoidosis in images from a to z with an explanation of their features and 
mechanisms of occurrence. Radiation diagnostics of pulmonary sarcoidosis is now 
a multimodal study with CT leading (as an expert technique) and supplementing, 
if necessary, radionuclide studies (SPECT, PET), ultrasound, MRI. Modern clas-
sical signs of SP (according to the Statement on Sarcoidosis, 1999) have changed 
their characteristics due to the widespread use of CT: variants of lymphadenopathy 
(features of the structure, localization of the affected lymph nodes), perilymphatic 
dissemination (manifestations of sarcoid alveolitis, types of foci), lesions pulmo-
nary interstitium. Radiation patterns of unfavorable forms of SP were revealed: 
fibrosing sarcoidosis (with a description of the variants of sarcoid fibrosis and their 
difference from other progressive pulmonary fibrosis) and progressive sarcoidosis 
(with the identification of possible causes of its occurrence and radiation patterns). 
For the convenience of interpreting changes in SP detected by CT, we proposed 
models of unfavorable forms of SP: interstitial edema (IO), idiopathic pulmonary 
fibrosis (IPF), hypersensitive pneumonitis (PP), their combination, pneumoco-
niosis and progressive SP. It was noted that the model of interstitial edema in SP is 
often combined with multisystem lesions (eyes, kidneys), and has a high risk of 
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developing interstitial fibrosis (transition to the IPF model). The main points to 
which a radiologist should draw a pulmonologist’s attention when performing a CT 
scan of the chest of a patient with sarcoidosis: describe all unfavorable models of 
sarcoidosis with the formation of fibrosis, expansion of cardiac cavities (indirect 
signs of cardiac sarcoidosis, especially in young patients, which requires MRI, or 
PET of the heart), signs of pulmonary hypertension (the causes of which may be 
vascular lesions in sarcoidosis and PE, which requires CT angiography, or SPECT), 
enlargement of the spleen (always within the scan area, may indicate additional 
hematological problems, both associated with sarcoidosis or not), identification of 
non-lymphotropic disseminations in sarcoidosis (a sign of comorbidity, requires 
CT in the whole body mode with multiphase contrast). Patients with sarcoidosis 
are seen by a pulmonologist and a thoracic radiologist, but the polysystemic 
nature of the lesion requires these specialists to know the signs of extrapulmonary 
manifestations of sarcoidosis (both clinical and radiation). If you suspect primary 
extrathoracic sarcoidosis (neurosarcoidosis, sarcoidosis of the kidneys, skin, eyes) 
in patients observed by doctors of other specialties, it is necessary to include not 
only a pulmonologist, but also a radiologist in the multidisciplinary consultation. 
Detection of radiation signs of comorbidity in sarcoidosis is especially important 
because it leads to a change in the tactics of patient management. The complexity of 
the layering of different types of pulmonary dissemination and lymphadenopathy 
and the multisystem nature of the lesion can be fully determined during a mul-
tidisciplinary consultation comprised of a pulmonologist and a radiologist with 
the involvement of an oncologist, neurologist, infectious disease specialist. The 
accumulation of experience in clinical and radiation examination of patients with 
sarcoidosis makes it possible to identify unfavorable clinical and radiological forms: 
fibrosing, progressive SP, as well as to assess its systemic manifestations and comor-
bidity, which is important for treatment tactics.
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